The Democratic Republic of the Congo has struggled with the second-deadliest outbreak of Ebola in the world. However, scientists began administering two new ebola treatments to all patients there.
These treatments, known as REGN-EB3 and mAb114, began testing in November. Proven to be effective, further testing on other drugs has halted. These results show that scientists are one step closer to curing Ebola. Over 1,800 people have already been killed by the deadly virus in the Congo, but that number is slowly ceasing to grow now.
The two drugs have an average mortality rate of 32%, as compared to their alternatives, ZMapp and Remdesivir, which have rates of 52%. According to Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), for patients being treated early, REGN-EB3 and mAb114 have mortality rates of just 6% and 11% respectively.
However, scientists have persisted that these are simply preliminary results. Extensive testing is still required. The WHO, in partnership with NIAID, will begin conducting a study among the people of the DRC to determine which of the two drugs works best. While the results are currently being determined, it can be inferred that Ebola will not continue to be one of the deadliest diseases in the world and will become one that it treatable and even preventable.